Enhanced therapeutic efficacy and memory of tumor-specific CD8 T cells by ex vivo PI3K-δ inhibition

Rasha Abu Eid, Shamim Ahmad, Yuan Lin, Mason Webb, Zuzana Berrong, Rajeev Kumar Shrimali, Takumi Kumai, Sudha Ananth, Paulo C. Rodriguez, Esteban Celis, John Edward Janik, Mikayel Mkrtichyan, Samir N. Khleif

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Inhibition of specific Akt isoforms in CD8þ T cells promotes favored differentiation into memory versus effector cells, the former of which are superior in mediating antitumor immunity. In this study, we investigated the role of upstream PI3K isoforms in CD8þ T-cell differentiation and assessed the potential use of PI3K isoform–specific inhibitors to favorably condition CD8þ T cells for adoptive cell therapy. The phenotype and proliferative ability of tumor antigen–specific CD8þ T cells was assessed in the presence of PI3K-a, -b, or -d inhibitors. Inhibition of PI3K-d, but not PI3K-a or PI3K-b, delayed terminal differentiation of CD8þ T cells and maintained the memory phenotype, thus enhancing their proliferative ability and survival while maintaining their cytokine and granzyme B production ability. This effect was preserved in vivo after ex vivo PI3K-d inhibition in CD8þ T cells destined for adoptive transfer, enhancing their survival and also the antitumor therapeutic activity of a tumor-specific peptide vaccine. Our results outline a mechanism by which inhibitions of a single PI3K isoform can enhance the proliferative potential, function, and survival of CD8þ T cells, with potential clinical implications for adoptive cell transfer and vaccine-based immunotherapies.

Original languageEnglish (US)
Pages (from-to)4135-4145
Number of pages11
JournalCancer Research
Volume77
Issue number15
DOIs
StatePublished - Aug 1 2017

Fingerprint

Phosphatidylinositol 3-Kinases
T-Lymphocytes
Aptitude
Neoplasms
Protein Isoforms
Adoptive Transfer
Therapeutics
Phenotype
Granzymes
Subunit Vaccines
Inhibition (Psychology)
Cell- and Tissue-Based Therapy
Immunotherapy
Cell Differentiation
Immunity
Vaccines
Cytokines

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Abu Eid, R., Ahmad, S., Lin, Y., Webb, M., Berrong, Z., Shrimali, R. K., ... Khleif, S. N. (2017). Enhanced therapeutic efficacy and memory of tumor-specific CD8 T cells by ex vivo PI3K-δ inhibition. Cancer Research, 77(15), 4135-4145. https://doi.org/10.1158/0008-5472.CAN-16-1925

Enhanced therapeutic efficacy and memory of tumor-specific CD8 T cells by ex vivo PI3K-δ inhibition. / Abu Eid, Rasha; Ahmad, Shamim; Lin, Yuan; Webb, Mason; Berrong, Zuzana; Shrimali, Rajeev Kumar; Kumai, Takumi; Ananth, Sudha; Rodriguez, Paulo C.; Celis, Esteban; Janik, John Edward; Mkrtichyan, Mikayel; Khleif, Samir N.

In: Cancer Research, Vol. 77, No. 15, 01.08.2017, p. 4135-4145.

Research output: Contribution to journalArticle

Abu Eid, R, Ahmad, S, Lin, Y, Webb, M, Berrong, Z, Shrimali, RK, Kumai, T, Ananth, S, Rodriguez, PC, Celis, E, Janik, JE, Mkrtichyan, M & Khleif, SN 2017, 'Enhanced therapeutic efficacy and memory of tumor-specific CD8 T cells by ex vivo PI3K-δ inhibition', Cancer Research, vol. 77, no. 15, pp. 4135-4145. https://doi.org/10.1158/0008-5472.CAN-16-1925
Abu Eid, Rasha ; Ahmad, Shamim ; Lin, Yuan ; Webb, Mason ; Berrong, Zuzana ; Shrimali, Rajeev Kumar ; Kumai, Takumi ; Ananth, Sudha ; Rodriguez, Paulo C. ; Celis, Esteban ; Janik, John Edward ; Mkrtichyan, Mikayel ; Khleif, Samir N. / Enhanced therapeutic efficacy and memory of tumor-specific CD8 T cells by ex vivo PI3K-δ inhibition. In: Cancer Research. 2017 ; Vol. 77, No. 15. pp. 4135-4145.
@article{934579666635484eb27d265a3cb3c29c,
title = "Enhanced therapeutic efficacy and memory of tumor-specific CD8 T cells by ex vivo PI3K-δ inhibition",
abstract = "Inhibition of specific Akt isoforms in CD8{\th} T cells promotes favored differentiation into memory versus effector cells, the former of which are superior in mediating antitumor immunity. In this study, we investigated the role of upstream PI3K isoforms in CD8{\th} T-cell differentiation and assessed the potential use of PI3K isoform–specific inhibitors to favorably condition CD8{\th} T cells for adoptive cell therapy. The phenotype and proliferative ability of tumor antigen–specific CD8{\th} T cells was assessed in the presence of PI3K-a, -b, or -d inhibitors. Inhibition of PI3K-d, but not PI3K-a or PI3K-b, delayed terminal differentiation of CD8{\th} T cells and maintained the memory phenotype, thus enhancing their proliferative ability and survival while maintaining their cytokine and granzyme B production ability. This effect was preserved in vivo after ex vivo PI3K-d inhibition in CD8{\th} T cells destined for adoptive transfer, enhancing their survival and also the antitumor therapeutic activity of a tumor-specific peptide vaccine. Our results outline a mechanism by which inhibitions of a single PI3K isoform can enhance the proliferative potential, function, and survival of CD8{\th} T cells, with potential clinical implications for adoptive cell transfer and vaccine-based immunotherapies.",
author = "{Abu Eid}, Rasha and Shamim Ahmad and Yuan Lin and Mason Webb and Zuzana Berrong and Shrimali, {Rajeev Kumar} and Takumi Kumai and Sudha Ananth and Rodriguez, {Paulo C.} and Esteban Celis and Janik, {John Edward} and Mikayel Mkrtichyan and Khleif, {Samir N.}",
year = "2017",
month = "8",
day = "1",
doi = "10.1158/0008-5472.CAN-16-1925",
language = "English (US)",
volume = "77",
pages = "4135--4145",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "15",

}

TY - JOUR

T1 - Enhanced therapeutic efficacy and memory of tumor-specific CD8 T cells by ex vivo PI3K-δ inhibition

AU - Abu Eid, Rasha

AU - Ahmad, Shamim

AU - Lin, Yuan

AU - Webb, Mason

AU - Berrong, Zuzana

AU - Shrimali, Rajeev Kumar

AU - Kumai, Takumi

AU - Ananth, Sudha

AU - Rodriguez, Paulo C.

AU - Celis, Esteban

AU - Janik, John Edward

AU - Mkrtichyan, Mikayel

AU - Khleif, Samir N.

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Inhibition of specific Akt isoforms in CD8þ T cells promotes favored differentiation into memory versus effector cells, the former of which are superior in mediating antitumor immunity. In this study, we investigated the role of upstream PI3K isoforms in CD8þ T-cell differentiation and assessed the potential use of PI3K isoform–specific inhibitors to favorably condition CD8þ T cells for adoptive cell therapy. The phenotype and proliferative ability of tumor antigen–specific CD8þ T cells was assessed in the presence of PI3K-a, -b, or -d inhibitors. Inhibition of PI3K-d, but not PI3K-a or PI3K-b, delayed terminal differentiation of CD8þ T cells and maintained the memory phenotype, thus enhancing their proliferative ability and survival while maintaining their cytokine and granzyme B production ability. This effect was preserved in vivo after ex vivo PI3K-d inhibition in CD8þ T cells destined for adoptive transfer, enhancing their survival and also the antitumor therapeutic activity of a tumor-specific peptide vaccine. Our results outline a mechanism by which inhibitions of a single PI3K isoform can enhance the proliferative potential, function, and survival of CD8þ T cells, with potential clinical implications for adoptive cell transfer and vaccine-based immunotherapies.

AB - Inhibition of specific Akt isoforms in CD8þ T cells promotes favored differentiation into memory versus effector cells, the former of which are superior in mediating antitumor immunity. In this study, we investigated the role of upstream PI3K isoforms in CD8þ T-cell differentiation and assessed the potential use of PI3K isoform–specific inhibitors to favorably condition CD8þ T cells for adoptive cell therapy. The phenotype and proliferative ability of tumor antigen–specific CD8þ T cells was assessed in the presence of PI3K-a, -b, or -d inhibitors. Inhibition of PI3K-d, but not PI3K-a or PI3K-b, delayed terminal differentiation of CD8þ T cells and maintained the memory phenotype, thus enhancing their proliferative ability and survival while maintaining their cytokine and granzyme B production ability. This effect was preserved in vivo after ex vivo PI3K-d inhibition in CD8þ T cells destined for adoptive transfer, enhancing their survival and also the antitumor therapeutic activity of a tumor-specific peptide vaccine. Our results outline a mechanism by which inhibitions of a single PI3K isoform can enhance the proliferative potential, function, and survival of CD8þ T cells, with potential clinical implications for adoptive cell transfer and vaccine-based immunotherapies.

UR - http://www.scopus.com/inward/record.url?scp=85026736606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026736606&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-16-1925

DO - 10.1158/0008-5472.CAN-16-1925

M3 - Article

C2 - 28615225

AN - SCOPUS:85026736606

VL - 77

SP - 4135

EP - 4145

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 15

ER -